Relenza (Zanamivir) Rotadisk, 5 mg

This is a NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT under the authority of FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. The Office of the Administration for Strategic Preparedness and Response (ASPR), Center for the Strategic National Stockpile (SNS) intends to award a sole source firm fixed price contract to: Manufacturer Name GlaxoSmithKline LLC 410 Blackwell St. Research Triangle Park Durham, NC, 27701 The purpose of this acquisition is to provide the United States Government (USG) with a pharmaceutical required to maintain minimum stockpiling capabilities for responding to public health events. Relenza (Zanamivir) Rotadisk, 5 mg are essential for readiness and response to national emergencies. Relenza (Zanamivir) is an antiviral drug that is active against both influenza type A and influenza type B viruses. Zanamivir is given by inhalation only. The USG has a need to procure Relenza (Zanamivir) Rotadisk, 5 mg, a U.S. Food and Drug Administration (FDA)-approved and commercial pharmaceutical, to be utilized during national public health events. The USG intends to procure the following: quantity of 303,333 packages of Relenza (Zanamivir) Rotadisk 5 mg for the base year, quantity of 303,333 packages of Relenza (Zanamivir) Rotadisk 5 mg for optional year 1, quantity of 303,333 packages of Relenza (Zanamivir) Rotadisk 5 mg for optional year 2, quantity of 303,333 packages of Relenza (Zanamivir) Rotadisk 5 mg for optional year 3, quantity of 303,333 packages of Relenza (Zanamivir) Rotadisk 5 mg for optional year 4. GlaxoSmithKline LLC is currently the sole manufacturer of Relenza (Zanamivir) Rotadisk, 5 mg. They have no relationships with resellers or distributors for this product. There are no other United States FDA-approved manufacturers for Relenza (Zanamivir) Rotadisk, 5 mg. This notice is for informational and planning purposes and does not constitute a solicitation. This notice of intent is NOT a request for competitive proposals. A determination by the Government not to compete this procurement based upon response(s) to this notice is solely within the discretion of the Government. Interested parties who believe they possess the capabilities to satisfy this requirement must submit in writing their name, address, telephone number, email, UEI/CAGE code, business size, National Drug Code (NDC), and a statement of capability demonstrating their abilities to meet this requirement. The Government will not be responsible for any costs incurred in responding to this notice. All responses must be received by September 20, 2025, at 3:00 PM Eastern Standard Time. All responses must be in writing and must be sent via email to OSContracting.hhs.gov . Reference Relenza (Zanamivir) Rotadisk, 5 mg Acquisition in the subject line. No other submissions will be accepted.